The earnings call presents a largely positive outlook for Altimmune, emphasizing significant advances in clinical trials, particularly for NASH, and a strong financial position. However, challenges remain in achieving statistical significance for fibrosis improvement and navigating regulatory pathways for noninvasive testing.

Company Guidance

In the Altimmune Second Quarter 2025 Financial Results Conference Call, several key metrics and updates were highlighted. The company reported $183.1 million in cash and cash equivalents, reflecting a 40% increase from the beginning of the year, bolstered by an $88 million equity capital raise and a $100 million Hercules debt facility. The IMPACT trial's 24-week data showed pembidutide achieved statistical significance in NASH resolution, demonstrating significant improvements in noninvasive markers of inflammation and fibrosis, liver fat reduction, and weight loss, while maintaining a strong safety and tolerability profile. R&D expenses for the quarter were $17.2 million, with $11.2 million directly attributed to pembidutide development. The company plans to leverage these data in their upcoming end-of-phase-two meeting with the FDA in Q4 2025. Additionally, Altimmune has initiated Phase II trials for AUD and ALD, focusing on the 2.4 mg weekly dose of pemphidutide, and plans to report full 48-week data later in the year.

IMPACT Trial Success

Pembiguate achieved statistical significance in the primary endpoint of NASH resolution and across multiple objective measures of efficacy, including noninvasive markers of inflammation and fibrosis, liver fat reduction, and weight loss at 24 weeks.

Strong Financial Position

Altimmune concluded the second quarter with $183.1 million in cash, marking a 40% increase over the start of the year, boosted by $88 million in gross equity capital and a $100 million Hercules debt facility.

Advancement in Phase II Trials

Phase II trials in Alcohol Use Disorder (AUD) and Alcohol-Associated Liver Disease (ALD) are underway, with promising potential given the unmet needs in these areas.

Potentially Class-Leading Safety and Tolerability

Pembiguate demonstrated excellent tolerability without dose titration, with only a single adverse event-related discontinuation in the treatment arms.

Altimmune (ALT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.27 / -	-0.32	―	―	―
Aug 12, 2025	2025 (Q2)	-0.34 / -0.27	-0.35	22.86% (+0.08)	―
May 13, 2025	2025 (Q1)	-0.35 / -0.26	-0.34	23.53% (+0.08)	―
Feb 27, 2025	2024 (Q4)	-0.33 / -0.33	-0.54	38.89% (+0.21)	―
Nov 12, 2024	2024 (Q3)	-0.36 / -0.32	-0.39	17.95% (+0.07)	―
Aug 08, 2024	2024 (Q2)	-0.35 / -0.35	-0.32	-9.37% (-0.03)	―
May 09, 2024	2024 (Q1)	-0.37 / -0.34	-0.4	15.00% (+0.06)	―
Mar 27, 2024	2023 (Q4)	-0.46 / -0.54	-0.43	-25.58% (-0.11)	―
Nov 07, 2023	2023 (Q3)	-0.45 / -0.39	-0.48	18.75% (+0.09)	―
Aug 10, 2023	2023 (Q2)	-0.47 / -0.32	-0.42	23.81% (+0.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$3.38	$3.62	+7.10%
May 13, 2025	$6.01	$5.76	-4.16%
Feb 27, 2025	$5.94	$6.42	+8.08%
Nov 12, 2024	$7.35	$9.49	+29.12%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Altimmune Inc (ALT) report earnings?

Altimmune Inc (ALT) is schdueled to report earning on Nov 11, 2025, TBA (Confirmed).

What is Altimmune Inc (ALT) earnings time?

Altimmune Inc (ALT) earnings time is at Nov 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALT EPS forecast?

ALT EPS forecast for the fiscal quarter 2025 (Q3) is -0.27.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing